PONTE VEDRA BEACH, Fla., Feb. 19, 2020 - RedDress, a privately held, Israel and U.S. based company, today announced the U.S. launch of ActiGraft, the first wound treatment that transforms – in real time – a patient's blood into an autologous whole blood clot tissue. Once applied, the blood clot tissue serves as a protective covering and supports wound healing processes which naturally occur in the patient's body. ActiGraft recently received 510(k) clearance from the U.S. Food and Drug Administration (FDA).
"We're incredibly proud to introduce ActiGraft to the wound care community," said Alon Kushnir, Founder and CEO of RedDress. "There's an estimated 6.5 million people in the U.S. suffering from severe, debilitating wounds and ulcers; the development of a treatment that replicates one's own natural healing process was our solution to address the community's unmet need and transform the way health care providers, patients, and their caregivers, manage hard-to-treat wounds and ulcers."
ActiGraft supports each stage of the wound healing process and delivers significant benefits in terms of comfort and cost. These benefits include:
ActiGraft can be used for a wide variety of hard-to-treat chronic wounds, including but not limited to:
Click Here to schedule a free demo of ActiGraft.
RedDress is a privately held, Israel-based company with a U.S. subsidiary, RedDress Inc., located in Ponte Vedra Beach, Florida. Founded in 2009 with the goal of developing more effective, natural and economically viable treatments for chronic wounds, RedDress is committed to improving the health and lives of patients around the world with its latest innovation – ActiGraft.